Back to top

Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim

Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares. The firm adjuste...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Adaptive Biotechnologies Corporation (ADPT)